Alk-rearranged lung adenocarcinoma: From molecular genetics to therapeutic targeting.

Tumori · 2024 · PMC11005315 · PMID 37772924

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

29 The results of this trial confirmed a highly significant effect of brigatinib in improving PFS in comparison with crizotinib (median PFS 24.0 vs 11.0 months, respectively). 30 Alectinib The second generation ALK TKI alectinib was explored in comparison of other ALK inhibitors or of chemotherapy.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.